Abiopharma

New Form 8-K - DYNAVAX TECHNOLOGIES CORP Filed: 2025-08-07 AccNo: 0001029142-25-000115 Size: 310 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

10x Genomics - 10x Genomics to Acquire Scale Biosciences

New Form 8-K - aTYR PHARMA INC Filed: 2025-08-07 AccNo: 0001339970-25-000007 Size: 443 KB Item 2.06: Material Impairments Item 9.01: Financial Statements and Exhibits

10x Genomics to Acquire Scale Biosciences

New Form S-8 - CYTOKINETICS INC Filed: 2025-08-07 AccNo: 0001193125-25-175412 Size: 202 KB

New Form 8-K - ARTELO BIOSCIENCES, INC. Filed: 2025-08-07 AccNo: 0001640334-25-001375 Size: 306 KB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 9.01: Financial Statements and Exhibits

Health Catalyst Reports Second Quarter 2025 Results

Ascendis Pharma Reports Second Quarter 2025 Financial Results

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2025 Financial Results

Design Therapeutics Highlights Progress Across LeadGeneTAC® Programs and Reports Second Quarter 2025 Financial Results

PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Teknova Reports Second Quarter 2025 Financial Results

IN8bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Tectonic Therapeutic Announces Second Quarter 2025 Financial Results and Recent Business Highlights

Arrowhead Pharmaceuticals Reports Fiscal 2025 Third Quarter Results